Haematological manifestations of COVID 19 And their prognostic significance- A Cross-Sectional Study

Nipun Bawiskar*1, Amol Andhale1, Sourya Acharya1, Sunil Kumar1, Samarth Shukla2

1Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed University), Wardha, Sawangi Meghe, 442001, Maharashtra, India
2Department of Pathology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed University), Wardha, Sawangi Meghe, 442001, Maharashtra, India

ABSTRACT

SARS-CoV2 started as pneumonia of unknown aetiology in Wuhan, China. Considered a respiratory pathogen primarily initially, COVID 19 is now identified as a systemic infection with significant effects on the hematopoietic system. Lymphopenia, peak platelet/ lymphocyte ratio and neutrophil/lymphocyte ratio are some of the parameters that could be considered as prognostic markers of the disease. Disseminated intravascular coagulation, along with elevated D-dimer levels, are commonly encountered and are usually associated with a worsening clinical picture. IL-6, C reactive protein and Lactate Dehydrogenase with high serum prolactin and serum ferritin levels project a dismal outcome. Venous thromboembolism occurs in both ambulatory and bedridden patients making thromboprophylaxis with LMWH popular. To correlate haematological parameters like lymphopenia, deranged coagulation profile and elevated d-dimer levels with the outcome (recovery or death) of the patients infected with SARS-CoV-2. In this prospective cross-sectional study, data will be gathered from patients found to be positive for COVID 19 with the duration of the study being four months. Lymphopenia, elevated D-dimer levels and deranged coagulation profile are expected in patients with COVID-19. Haematological parameter like lymphopenia raised D-dimer levels, and deranged coagulation profile are associated with poor prognosis in COVID 19.

INTRODUCTION

COVID 19 is a disease entity caused by SARS-CoV2 that started in Wuhan, the capital of Hubei province in China initially unrecognized as a cluster of pneumonia cases of unknown aetiology (Zhu et al., 2020). Initially spreading to other areas in China and Asia, it has now come to dominate the world, causing significant morbidity and mortality along its way. It is transmitted from one person to another via droplets and direct human-to-human contact. On entering the host, it binds to specific receptors like angiotensin-converting enzyme-2 receptor (for which it has high affinity) and an alternate receptor CD209L. ACE 2 receptors are mainly present on the epithelium of trachea, bronchi, alveoli and macrophages. The virus enters the cells and begins to replicate, following which mature virions are released. These, in turn, infect other cells causing initiation of a wide array of symptoms as the cycle
continues (Chan et al., 2020; Xu et al., 2020). Chiefly thought of as a respiratory pathogen, emerging data has now come to suggest that COVID-19 is a systemic disease involving the gastrointestinal, cardiovascular, neurological, immune and hematopoietic systems as well (Drippin et al., 2020; Bangash et al., 2020; Mehta et al., 2020).

Disseminated intravascular coagulation, lymphopenia, elevated D-dimer levels are some of the parameters usually associated with a worsening clinical picture. Lactate Dehydrogenase, high serum prolactin, serum ferritin levels and IL-6 may also be considered as prognostic markers in the disease.

Research indicates that mortality is significantly higher in older individuals with comorbidities, but younger individuals may also succumb if they present with lethal complications like DIC and myocarditis (Tang et al., 2020b; Madjid et al., 2020).

**Aim and objectives**

To study the haematological parameters in COVID-19 disease. To correlate haematological parameters like lymphopenia, deranged coagulation profile and elevated D-dimer levels with the outcome of the patients infected with SARS-CoV-2.

**Outcome**

The outcomes will be categorized as; recovery and death.

**MATERIALS AND METHODS**

**Settings**

This cross-sectional study will be conducted in Datta Meghe Institute of medical sciences, J.N.Medical College, Sawangi, Wardha; a rural tertiary care medical teaching institute in central India. The hospital is a designated treatment centre for COVID-19 in Wardha district. Duration of the study will be four months. The study will be conducted after approval from the institutional ethical committee.

**Study participants**

Consecutive subjects aged more than 16 years who will present to the hospital with symptoms and signs of COVID-19, which will be confirmed after positive throat/nasal swab will form the study group. Written informed consent (by signature or thumbprint) will be obtained from all participants.

**Exclusion Criteria**

1. Haematological malignancies
2. Coagulation disorders
3. Postoperative patients
4. Age less than 16 years of age will be excluded from the study.

A detailed history will be taken, and the examination will be done fulfilling all the proposed guidelines. The swab will be sent to check for infection with SARS-CoV-2. All routine investigations will be sent including CBC, coagulation profile and D-dimer levels.

**Sample size**

Patients found positive for COVID 19 will be included in the study. The study will be done for four months.

**DISCUSSION**

**Blood Counts and Biochemistry Findings**

In the initial phase of the disease patients present with non-specific symptoms and a picture suggestive of hyperactivity followed by depletion of CD8 and T cells (Zheng et al., 2020; Qin et al., 2020).

Yang et al. studied 52 critically ill patients and found that about 85% had lymphopenia (Yang et al., 2020). A similar blood picture was seen in the ICU patients studied in Singapore (p <0.0001) (Fan et al., 2020). Lymphopenia was more severe in patients who ultimately succumbed to the disease (Wang et al., 2020).

This was also apparent in studies conducted in The United States of America (Arentz et al., 2020; Bhatraju et al., 2020). Qin et al. (2020) and Deng et al. (2020) reported decreased lymphocyte/WBC ratio in those with severe disease. High leukocytes, low platelets and low lymphocytes are found in patients with myocardial injury (Shi et al., 2020; Guo et al., 2020). In Wuhan, 187 patients were evaluated and were found to have high troponin T levels associated with leukocytosis, lymphopenia and increased neutrophil counts (Guo et al., 2020). Based on a meta-analysis involving nine studies, thrombocytopenia is directly associated with the severity of SARS-CoV2 infection (Lippi et al., 2020). A peak in platelet count during the disease was linked with a worse outcome. Cytokine storm causes platelet activation, which in turn results in a high platelet to lymphocyte ratio now considered a prognostic marker (Qu et al., 2020).

Following a study conducted in China raised CRP, Procalcitonin and LDH were found in 60.7%, 5.5% and 41% of the cases, respectively (Guan et al., 2020). Zhou et al. studied 191 patients and found higher levels of LDH, IL-6 and serum ferritin in those that succumbed (Zhou et al., 2020). Elevated LDH levels were indicative of the need for ICU support, imminent ARDS and a higher risk of death (Yang et al., 2020).
et al., 2020; Fan et al., 2020; Wu et al., 2019). Raised CRP levels are also linked with the same, in addition to raised Troponin T levels and myocardial injury (Deng et al., 2020; Shi et al., 2020; Wu et al., 2019).

A positive correlation was found between serum ferritin levels, the risk of development of ARDS and probable death (Zhou et al., 2020; Wu et al., 2019). IL-6 levels were found to demonstrate a similar likelihood.

Coagulation complications

Elevated D-dimer levels were found in around 36% of the total number of cases assessed in a study in China (Chen et al., 2020b). Those with High prothrombin time and D dimer levels on admission were more likely to require ICU support during their hospital stay (Huang et al., 2020). Wang et al. (2020) demonstrated the same in his analysis.

Those with cardiac disorders are more likely to develop coagulation disorders as compared to those without cardiac involvement (Shi et al., 2020). Raised D-dimer, Troponin T and a deranged coagulation profile were associated with increased risk of death and ARDS (Zhou et al., 2020; Wu et al., 2019; Guo et al., 2020). Sequential rise in D-dimer raised fibrin degradation products, APTT and PT were apparent among non-survivors (Tang et al., 2020b; Zhou et al., 2020). Therefore disseminated intravascular coagulation and D-dimer elevation are seen with severe SARS-CoV2 infection (Lippi and Favaloro, 2020). Endothelial dysfunction and immune deregulation play a part in the pathophysiology of the disease (Lillicrap, 2020). In acutely ill hospitalized patients, the rate of symptomatic VTE is up to 10% (Kahn et al., 2012). The risk of VTE goes up in the presence of cardiovascular risk factors and diseases, acute inflammatory states, prolonged immobilization, classical genetic thrombophilia and history of VTE. Increase in blood viscosity occurs as a result of the release of certain hormones, immunoglobulins and inflammatory mediators in acutely ill patients: mechanical ventilation, surgery and central venous catheterization cause Vascular endothelial damage. A combination of these results in DVT and could lead to pulmonary embolism. Thromboprophylaxis is hence important and can be used prophylactically in these patients (Witt et al., 2018). Early diagnosis and treatment are important in patients who develop PE to prevent morbidity and mortality. D- dimer, USG venous Doppler, bedside echo etc. can be used in patients with PE/DVT. CT pulmonary angiography confirmed cases of PE had higher D-dimer levels as compared to those without PE (Chen et al., 2020a). Unfractionated heparin or low molecular weight heparin are preferred over direct oral anticoagulants due to drug-drug interaction with concomitant antiviral and antibacterial treatment (Thachil et al., 2020). The antithrombotic effect may be reduced, or bleeding risk may increase if treatments interfere with CYP3A4 and P-gp pathways. Tang et al. demonstrated the efficacy of LMWH in patients with markedly elevated D-dimer levels or those meeting the criteria for DIC (Tang et al., 2020a). Heparin-induced thrombocytopenia must be looked for in patients treated with heparin using 4T score (thrombocytopenia, the timing of fall in platelet count, thrombosis and other causes of thrombocytopenia). The incidence has not been looked into, but there is increased risk given immune dis-regulation, neutrophil extracellular traps, platelet factor 4 release and inflammatory syndrome.

CONCLUSION

Haematological parameters like lymphopenia, deranged coagulation profile and elevated D dimer levels are associated with poor prognosis in patients infected with SARS-CoV-2. NLR (neutrophil-lymphocyte ratio ) >3.13 is indicative of severe disease. Platelet counts also have a significant effect on the overall outcome of the patients. An increase in the platelet counts is associated with a decrease in mortality.

ACKNOWLEDGEMENT

I would like to thank my guide Dr Sourya Acharya sir, for his constant support throughout the study. I would also like to thank the patients who participated in the study and contributed to the understanding of COVID 19 and the effects of the same on the haematological parameters. Last but not least, I would like to acknowledge the Health care workers involved in the collection of samples and the care of the involved participants without whom the study would not have been possible.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

This study received no external funding for this study.

REFERENCES

Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., Lee, M. 2020. Characteristics and
Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA*, 323(16):1612–1614.

Bangash, M. N., Patel, J., Parekh, D. 2020. COVID-19 and the liver: little cause for concern. *The Lancet Gastroenterology & Hepatology*, 5(6):529–530.

Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pippavath, S., Wurfel, M. M., Evans, L., Kritek, P. A., West, T. E., Luks, A., Gerbino, A., Dale, C. R., Goldman, J. D., O’Mahony, S., Mikacenic, C. 2020. COVID-19 in Critically Ill Patients in the Seattle Region — Case Series. *New England Journal of Medicine*, 382(21):2012–2022.

Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., et al. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*, 395(10223):514–523.

Chen, J., Wang, X., Zhang, S., Liu, B., Wu, X., Wang, Y., Xie, Y., et al. 2020a. Findings of acute pulmonary embolism in COVID-19 patients. *Lancet Infectious Diseases*. SSRN Electronic Library-3548771.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., Zhang, L. 2020b. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*, 395(10223):507–513.

Deng, Y., Liu, W., Liu, K., Fang, Y. Y., Shang, J., Zhou, L., Wang, K., Leng, F., Wei, S., Chen, L., Liu, H. G. 2020. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. *Chinese Medical Journal*, 133(11):1261–1267.

Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Nigohosian, C. D., Zidar, D. A., Haythe, J., Brodie, D., Beckman, J. A., Kirtane, A. J., Stone, G. W., Krumholz, H. M., Parikh, S. A. 2020. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *Journal of the American College of Cardiology*, 75(18):2352–2371.

Fan, B. E., Chong, V. C. L., Chan, S. S. W., Lim, G. H., Lim, K. G. E., Tan, G. B., Mucheli, S. S., Kuperan, P., Ong, K. H. 2020. Hematologic parameters in patients with COVID-19 infection. *American Journal of Hematology*, (6):95–95.

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K. Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., Zhong, N. 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*, 382(18):1708–1720.

Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., Lu, Z. 2020. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*, 5(7):811–818.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Cao, B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. *China. The Lancet*, 395(10223):497–506.

Kahn, S. R., Lim, W., Dunn, A. S., Cushman, M., Dentai, F., Akel, E. A., Cook, D. J., Balekian, A. A., Klein, R. C., Le, H., Schulman, S., Murad, M. H. 2012. Prevention of VTE in Nonsurgical Patients. *Chest*, 141(2):e1955s–e226s.

Lillicrap, D. 2020. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. *Journal of Thrombosis and Haemostasis*, 18(4):786–787.

Lippi, G., Favaloro, E. J. 2020. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. *Thrombosis and Haemostasis*, 120(05):876–878.

Lippi, G., Plebani, M., Henry, B. M. 2020. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clinica Chimica Acta*, 506:145–148.

Madjid, M., Safavi-Naeini, P., Solomon, S. D., Vardeny, O. 2020. Potential Effects of Coronaviruses on the Cardiovascular System. *JAMA Cardiology*, 5(7):831–831.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*, 395(10229):1033–1034.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., Tian, D. S. 2020. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases*, 71(15):762–768.

Qu, R., Ling, Y., Zhang, Y., Wei, L., Chen, X., Li, X., Liu, X., Liu, H., Guo, Z., Ren, H., Wang, Q. 2020. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. *Journal of Medical Virology*, 92(9):1533–1541.

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., Huang, H., Yang, B., Huang, C. 2020. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19.
in Wuhan, China. *JAMA Cardiology*, 5(7):802–810.

Tang, N., Bai, H., Chen, X., Gong, J., Li, D., Sun, Z. 2020a. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease in 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*, 18(5):1094–1099.

Tang, N., Li, D., Wang, X., Sun, Z. 2020b. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, 18(4):844–847.

Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., Clark, C., Iba, T. 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*, 18(5):1023–1026.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z. 2020. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 323(11):1061–1069.

Witt, D. M., Nieuwlaat, R., Clark, N. P., Ansell, J., Holbrook, A., Skov, J., Shehab, N., Mock, J., Myers, T., Dentali, F., Crowther, M. A., Agarwal, A., Bhatt, M., Khatri, R., Riva, J. J., Zhang, Y., Guyatt, G. 2018. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Advances*, 2(22):3257–3291.

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Song, Y. 2019. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease. *JAMA Internal Medicine*, 180(7):934–943.

Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., Hao, P. 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modelling of its spike protein for risk of human transmission. *Science China Life Sciences*, 63(3):457–460.

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., Shang, Y. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centre, retrospective, observational study. *The Lancet Respiratory Medicine*, 8(5):475–481.

Zheng, H. Y., Zhang, M., Yang, C. X., Zhang, N., Wang, X. C., Yang, X. P., Dong, X. Q., Zheng, Y. T. 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cellular & Molecular Immunology*, 17(5):541–543.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 395(10299):1045–1062.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*, 382(8):727–733.